Pharmacology of bisphosphonates

Abstract

The biological effects of the bisphosphonates (BPs) as inhibitors of calcification and bone resorption were first described in the late 1960s. In the 50 years that have elapsed since then, the BPs have become the leading drugs for the treatment of skeletal disorders characterized by increased bone resorption, including Paget's disease of bone, bone metastases, multiple myeloma, osteoporosis and several childhood inherited disorders. The discovery and development of the BPs as a major class of drugs for the treatment of bone diseases is a paradigm for the successful journey from "bench to bedside and back again". Several of the leading BPs achieved "blockbuster" status as branded drugs. However, these BPs have now come to the end of their patent life, making them highly affordable. The opportunity for new clinical applications for BPs also exists in other areas of medicine such as ageing, cardiovascular disease and radiation protection. Their use as inexpensive generic medicines is therefore likely to continue for many years to come. Fifty years of research into the pharmacology of bisphosphonates have led to a fairly good understanding about how these drugs work and how they can be used safely in patients with metabolic bone diseases. However, while we seemingly know much about these drugs, a number of key aspects related to BP distribution and action remain incompletely understood. This review summarizes the existing knowledge of the (pre)clinical and translational pharmacology of BPs, and highlights areas in which understanding is lacking.

The osteoclast cytoskeleton – current understanding and therapeutic perspectives for osteoporosis

“…Molecules of the bisphosphonate family are the most widely used drugs to control osteoclast activity; these pyrophosphate analogues incorporate into bone matrix and are ingested by the bone-degrading osteoclasts, causing their apoptosis (Cremers et al, 2019).…”

Biofunctionalization of Textile Materials. 2. Antimicrobial Modification of Poly(lactide) (PLA) Nonwoven Fabricsby Fosfomycin

“…Inhibition of osteoclastic bone resorption [48][49][50][51] The first and most abundant natural AA P [32,33] Phosphino-thricin Glu γP(Me) (phosphino-thricin, PPT) [ [42][43][44][45][46] ϖ-Aminoalkylphosphonic acids (ϖ-AA P )…”

Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases

“…The chemical structure of bisphosphonates, consisting of a P-C-P group (instead of a P-O-P group) ensures their rapid uptake by bone. Following the administration of oral bisphosphonates, approximately 50% of the dose is excreted by the kidneys, with the remaining bisphosphonate being taken up by bone resulting in an effective concentration of drug of up to 1000 mM within the resorption lacunae [ 48 , 49 ]. Bisphosphonates are currently used in the treatment of metastases from breast and prostate cancer, as well as in the treatment of multiple myeloma.…”